Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 4/20 | 0.47 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.43 |
| ▸ | GALR3 | O60755 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18850703 | 0.88 | HDAC9 (0.46) | TNFNOD1NPC1NOD2DHODH | |
| SCHEMBL18850709 | 0.77 | HTT (0.54) | TNFNOD1NPC1NOD2RAB9A | |
| SCHEMBL15839075 | 0.76 | SIGMAR1 (0.41) | DHODHHDAC9 | |
| SCHEMBL18850711 | 0.75 | TNF (0.58) | TNFNOD1NPC1NOD2RAB9A | |
| SCHEMBL23934809 | 0.75 | USP7 (0.56) | TNFNOD1NPC1NOD2RAB9A | |
| SCHEMBL14688575 | 0.75 | MAPK14 (0.40) | NPC1RAB9ADHODHHDAC9 | |
| SCHEMBL7961456 | 0.70 | USP7 (0.51) | NPC1RAB9APOLBHDAC9 | |
| SCHEMBL31011172 | 0.69 | TP53 (0.60) | NPC1RAB9A | |
| SCHEMBL16911954 | 0.68 | NPC1 (0.38) | TNFNOD1NPC1RAB9ADHODH | |
| SCHEMBL15838966 | 0.68 | CYP11B1 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300882-A1 | MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-09-30 | — | — | US | disclosed |
| WO-2017019772-A1 | MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2017-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300882-A1 | MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF | MYC, MYCBP, MLYCD | TNF 4438/4885NOD1 4010/4885NPC1 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.